News|Videos|September 30, 2026

From Engagement to Enterprise Value: Reframing Community as a Growth Segment

Community engagement is a powerful tool but its impact depends on how it is done. When it begins early, is sustained over time, and is built through organizations and individuals communities already trust, it can expand access to historically overlooked and medically underserved populations worldwide. The result is more representative science, stronger participation across the drug-development lifecycle, and a sustainable pathway to commercial growth. Inside Edge’s proprietary global Trustmaker Network turns trusted community relationships into meaningful action helping people make informed health decisions while delivering measurable outcomes across R&D and commercial. Email us at hello@insideedgeconsulting.com to discover how trusted community relationships can advance your next initiative.


Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.